OS Therapies Strengthens Strategic Advisory Board with Industry Luminaries Craig Eagle and Robert Langer
Key Insights
OS Therapies appointed Craig Eagle, MD, Chief Medical Officer of Guardant Health, and Robert "Bob" Langer, PhD, co-founder of Moderna, to its newly-formed strategic advisory board in April 2026.
The advisory board will guide regulatory execution for OST-HER2 in osteosarcoma (search) and help prioritize the company's clinical pipeline across multiple cancer indications.
OST-HER2 demonstrated statistically significant benefits in 12-month event-free survival and overall survival in its Phase 2b trial for recurrent, fully resected lung metastatic osteosarcoma (search).
OS Therapies, Inc. (NYSE American: OSTX) has significantly strengthened its strategic leadership by appointing two biotechnology industry veterans to its newly-formed strategic advisory board. The company announced the appointments of Craig Eagle, MD, Chief Medical Officer of Guardant Health, on April 8, 2026, followed by Robert "Bob" S. Langer, PhD, co-founder of Moderna, on April 13, 2026.
Strategic Advisory Board Formation
The strategic advisory board was established to assist OS Therapies in fine-tuning its osteosarcoma (search) regulatory execution plan and developing a detailed pipeline development strategy. The company currently maintains clinical-stage pipeline assets across multiple oncology indications, including breast cancer (search), colorectal cancer (search), non-small cell lung cancer (search), prostate cancer (search), and HPV-related cancers (search).
"Given Dr. Eagle's expertise in oncology therapeutic and biomarker development, we are very pleased to be able to leverage his experience as we engage with global regulators on the utility of our biomarker data to drive the regulatory process forward," said Paul Romness, MPH, Chair & CEO of OS Therapies.
Clinical Leadership Expertise
Dr. Craig Eagle brings extensive regulatory, clinical, and commercial expertise in therapeutics and biomarkers from his senior leadership roles at Guardant Health, Genentech, and Pfizer. At Genentech, he oversaw medical programs across the oncology portfolio and developed innovative cancer trials and strategies in personalized healthcare. His experience at Pfizer included serving as oncology business lead for the United Kingdom and Canada, global lead for Oncology Strategic Alliances and Partnerships, and global head of the Oncology Therapeutic Area Global Medical and Outcomes Group.
"Having been privy to the biomarker data from the Phase 2b trial, I am confident in the direction the Company is going and its prospects in osteosarcoma (search) and beyond," Dr. Eagle stated.
Scientific Innovation Leadership
Dr. Robert Langer, one of nine Institute Professors at MIT and the most cited engineer in history with an h-index of 336, will focus on listeria oncology pipeline prioritization and combinations with other oncology-focused biotechnologies. His pioneering work includes isolating the first angiogenesis inhibitors, creating the first nanoparticles for delivering large molecules, and helping establish the field of tissue engineering.
"Listeria's unique properties as an intracellular bacterium create major opportunities both to treat cancers which have not responded to existing immunotherapies and to enhance outcomes for patients already receiving other anti-cancer agents," Dr. Langer explained.
OST-HER2 Clinical Success
The company's lead asset, OST-HER2, demonstrated statistically significant benefit in the 12-month event-free survival primary endpoint and overall survival secondary endpoint in its Phase 2b clinical trial for recurrent, fully resected, lung metastatic osteosarcoma (search). The immunotherapy leverages the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 (search) protein.
OST-HER2 has received multiple regulatory designations, including Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA, as well as Orphan Drug Designation, Fast Track Designation, and ATMP from the European Medicines Agency (search).
Regulatory Timeline and Commercial Prospects
OS Therapies anticipates receiving a Biologics License Application from the FDA for OST-HER2 in osteosarcoma (search) in 2026. Under the Rare Pediatric Disease Designation program, approval would make the company eligible to receive a Priority Review Voucher that it intends to sell. The most recent publicly disclosed Priority Review Voucher transaction occurred in February 2026 at a reported value of $205 million.
The company also anticipates receiving Conditional Marketing Authorizations from the U.K.'s Medicines and Healthcare products Regulatory Agency and the European Medicines Agency (search) for OST-HER2 in 2026.
Advanced Technology Platforms
Beyond its listeria-based immunotherapies, OS Therapies is advancing next-generation tunable Antibody Drug Conjugate (tADC) technology. This platform leverages the company's proprietary silicone Si-Linker and Conditionally Active Payload technology, enabling the delivery of multiple payloads per linker.
Dr. Langer highlighted the potential of this technology: "The unique properties of silicone dioxide that underlie the tADC linker/cap technology present tremendous opportunities to design more comprehensive and efficacious candidates which can deliver combinations of cytotoxic and immune stimulatory compounds in a targeted way."
The company also anticipates reading out data from a Phase 1b study of OST-504 (search) in castration-resistant prostate cancer (search) in the first half of 2026, further expanding its clinical pipeline in oncology.